Drug-induced changes and disorders of sleep and wake cycles – a narrative review

Česká verze

Authors: K. Šonka ¹; M. Pretl ²; K. Seltenreichová ³; J. Slonková ⁴; J. Bušková ^5,6; S. Dostálová ¹
Authors place of work: Neurologická klinika a Centrum klinických neurověd 1. LF UK a VFN v Praze ¹; Inspamed, Praha ²; Neurologické oddělení Nemocnice Na Homolce, Praha ³; Neurologická klinika LF OU a FN Ostrava ⁴; Národní ústav duševního zdraví, Klecany ⁵; 3. LF UK, Praha ⁶
Published in the journal: Cesk Slov Neurol N 2025; 88(3): 143-152
Category: Minimonografie
doi: https://doi.org/10.48095/cccsnn2022143

Summary

Sleep and wake cycle changes are common adverse effects of medications and can be classified into nosological groups of insomnia, hypersomnolence, sleep-related breathing disorders, parasomnias, and sleep-related movement disorders according to the International Classification of Sleep Disorders, 3^rd edition, Text Revision. This review article enumerates which medications can induce sleep-wake cycle abnormalities and diseases and outlines how these adverse effects occur.

Keywords:

sleep – pharmacodynamics – adverse drug reaction – wake

Zdroje

1. American Academy of Sleep Medicine. The AASM International classification of sleep disorders –⁠ third edition, text revision (ICSD-3-TR). [online]. Dostupné z: https: //aasm.org/clinical-resources/international-classification-sleep-disorders/.

2. Riemann D, Espie CA, Altena E et al. The European Insomnia Guideline: an update on the diagnosis and treatment of insomnia 2023. J Sleep Res 2023; 32 (6): e14035. doi: 10.1111/jsr.14035.

3. Schweitzer PK, Malhotra R. Clinical pharmacology of drugs that affect sleep and wake. In: Kryger M, Roth T, Goldstein C et al. (eds). Principles and practice of sleep medicine. Philadelphia: Elsevier 2022 : 519–547.

4. Scheer FA, Morris CJ, Garcia JI et al. Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial. Sleep 2012; 35 (10): 1395–1402. doi: 10.5665/sleep.2122.

5. Chang CH, Yang YH, Lin SJ et al. Risk of insomnia attributable to beta-blockers in elderly patients with newly diagnosed hypertension. Drug Metab Pharmacokinet 2013; 28 (1): 53–58. doi: 10.2133/dmpk.dmpk-12 -⁠ rg-004.

6. Zeng Z, Yang Y, Zhang Y et al. Effect of antihypertensive medications on sleep status in hypertensive patients. Sleep Biol Rhythms 2022; 20 (4): 473–480. doi: 10.1007/s41105-022-00391-8.

7. Jarrin DC, Alvaro PK, Bouchard MA et al. Insomnia and hypertension: a systematic review. Sleep Med Rev 2018; 41 : 3–38. doi: 10.1016/j.smrv.2018.02.003.

8. Broncel M, Gorzelak-Pabis P, Sahebkar A et al. Sleep changes following statin therapy: a systematic review and meta-analysis of randomized placebo-controlled polysomnographic trials. Arch Med Sci 2015; 11 (5): 915–926. doi: 10.5114/aoms.2015.54841.

9. Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388 (10059): 2532–2561. doi: 10.1016/S0140-6736 (16) 31357-5.

10. Demisch L, Demisch K, Nickelsen T. Influence of dexamethasone on nocturnal melatonin production in healthy adult subjects. J Pineal Res 1988; 5 (3): 317–322. doi: 10.1111/j.1600-079x.1988.tb00657.x.

11. Chahine LM, Daley J, Horn S et al. Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson’s disease. Parkinsonism Relat Disord 2013; 19 (10): 859–863. doi: 10.1016/j.parkreldis.2013.05.009.

12. Neider I, Chaudhuri KR. Sleep dysfunction. In: Pahwa R, Lyons KE (eds). Handbook of Parkinsons disease. London: Informa Healthcare 2007 : 901–1107.

13. Hosenbocus S, Chahal R. Amantadine: a review of use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2013; 22 (1): 55–60.

14. Bassetti C, McNicholas W, Paunio T et al. Sleep medicine textbook. European Sleep Research Society 2021.

15. Lydic R, Hillman D, Jiang Y et al. Opioid actions on sleep and breathing. In: Kryger M, Roth T, Goldstein CA et al. (eds). Principles and practice of sleep medicine. Philadelphia: Amsterdam: Elsevier 2022 : 510–518.

16. Rosen IM, Aurora RN, Kirsch DB et al. Chronic opioid therapy and sleep: an American Academy of Sleep Medicine Position Statement. J Clin Sleep Med 2019; 15 (11): 1671–1673. doi: 10.5664/jcsm.8062.

17. Liguori C, Toledo M, Kothare S. Effects of anti-seizure medications on sleep architecture and daytime sleepiness in patients with epilepsy: a literature review. Sleep Med Rev 2021; 60 : 101559. doi: 10.1016/j.smrv.2021.101559.

18. Zhou JY, Tang XD, Huang LL et al. The acute effects of levetiracetam on nocturnal sleep and daytime sleepiness in patients with partial epilepsy. J Clin Neurosci 2012; 19 (7): 956–960. doi: 10.1016/j.jocn.2011.09.032.

19. Onakpoya IJ, Thomas ET, Lee JJ et al. Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials. BMJ Open 2019; 9 (1): e023600. doi: 10.1136/bmjopen-2018-023600.

20. Wang YG, Swick TJ, Carter LP et al. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med 2009; 5 (4): 365–371.

21. Brown MA, Guilleminault C. A review of sodium oxybate and baclofen in the treatment of sleep disorders. Curr Pharm Des 2011; 17 (15): 1430–1435. doi: 10.2174/138161211796197098.

22. Fuller PM, Dauvilliers Y. Histamine. In: Kryger M, Roth T, Goldstein CA et al. (eds). Principles and practice of sleep medicine. Philadelphia: Elsevier 2022 : 483–487.

23. Frucht S, Rogers JD, Greene PE et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52 (9): 1908–1910. doi: 10.1212/wnl.52.9.1908.

24. Vaseghi S, Arjmandi-Rad S, Nasehi M et al. Cannabinoids and sleep-wake cycle: the potential role of serotonin. Behav Brain Res 2021; 412 : 113440. doi: 10.1016/j.bbr.2021.113440.

25. Seda G, Tsai S, Lee-Chiong T. Medication effects on sleep and breathing. Clin Chest Med 2014; 35 (3): 557–569. doi: 10.1016/j. ccm.2014.06.011.

26. Jullian-Desayes I, Revol B, Chareyre E et al. Impact of concomitant medications on obstructive sleep apnoea. Br J Clin Pharmacol 2017; 83 (4): 688–708. doi: 10.1111/bcp.13153.

27. Feldman NT. Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing. Sleep Breath 2010; 14 (1): 77–79. doi: 10.1007/s11325-009-0283-1.

28. Javaheri S, Randerath WJ, Safwan Badr M et al. Medication-induced central sleep apnea: a unifying concept. Sleep 2024; 47 (8): zsae038. doi: 10.1093/sleep/zsae038.

29. Farney RJ, Walker JM, Cloward TV et al. Sleep-disordered breathing associated with long-term opioid therapy. Chest 2003; 123 (2): 632–639. doi: 10.1378/chest.123.2.632.

30. Hassamal S, Miotto K, Wang T et al. A narrative review: the effects of opioids on sleep disordered breathing in chronic pain patients and methadone maintained patients. Am J Addict 2016; 25 (6): 452–465. doi: 10.1111/ajad.12424.

31. Revol B, Jullian-Desayes I, Cracowski JL et al. Gabapentinoids and sleep apnea syndrome: a safety signal from the WHO pharmacovigilance database. Sleep 2019; 42 (2). doi: 10.1093/sleep/zsy242.

32. Finnimore AJ, Roebuck M, Sajkov D et al. The effects of the GABA agonist, baclofen, on sleep and breathing. Eur Respir J 1995; 8 (2): 230–234. doi: 10.1183/09031936.95.08020230.

33. Khazaie H, Sharafkhaneh A, Khazaie S et al. A weight-independent association between atypical antipsychotic medications and obstructive sleep apnea. Sleep Breath 2018; 22 (1): 109–114. doi: 10.1007/s11325-017-1537-y.

34. Snobrova B, Burdova K, Weiss V et al. Screening for sleep apnoea risk in testosterone-treated transgender men. Front Neurol 2023; 14 : 1289429. doi: 10.3389/fneur.2023.1289429.

35. Stallman HM, Kohler M, White J. Medication induced sleepwalking: a systematic review. Sleep Med Rev 2018; 37 : 105–113. doi: 10.1016/j.smrv.2017.01.005.

36. Bušek P, Bušková J. Záchvatové projevy ve spánku. Neurol Prax 2022; 23 (3): 203–210. doi: 10.36290/neu.2022. 007.

37. Hoque R, Chesson AL. Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J Clin Sleep Med 2009; 5 (5): 471–476.

38. Irfan M, Schenck CH, Howell MJ. NonREM disorders of arousal and related parasomnias: an updated review. Neurotherapeutics 2021; 18 (1): 124–139. doi: 10.1007/s13311-021-01011-y.

39. Ghosh D, Petrecca AM, Khuhro AL. Sleep-Related Eating Disorder (SRED): paradoxical effect of clonazepam. J Clin Sleep Med 2018; 14 (7): 1261–1263. doi: 10.5664/jcsm.7242.

40. Chopra A, Patel RS, Baliga N et al. Sleepwalking and sleep-related eating associated with atypical antipsychotic medications: case series and systematic review of literature. Gen Hosp Psychiatry 2020; 65 : 74–81. doi: 10.1016/j.genhosppsych.2020.05.014.

41. Abad VC. An evaluation of sodium oxybate as a treatment option for narcolepsy. Expert Opin Pharmacother 2019; 20 (10): 1189–1199. doi: 10.1080/14656566. 2019.1617273.

42. Němcová V, Šonka K. Fyziologie spánku. In: Nevšímalová S, Šonka K (eds). Poruchy spánku a bdění. Praha: Galén 2020 : 21–50.

43. Frauscher B, Jennum P, Ju YE et al. Comorbidity and medication in REM sleep behavior disorder: a multicenter case-control study. Neurology 2014; 82 (12): 1076–1079. doi: 10.1212/WNL.00000000000 00247.

44. McCarter SJ, St Louis EK, Sandness DJ et al. Antidepressants increase REM sleep muscle tone in patients with and without REM sleep behavior disorder. Sleep 2015; 38 (6): 907–917. doi: 10.5665/sleep.4738.

45. Akindele MO, Evans J, Oswald I. Monoamine oxidase inhibitors and sleep. Electroencephalogr Clin Neurophysiol 1970; 28 (4): 429.

46. Lam SP, Zhang J, Li SX et al. RBD, antidepressant medications, and psychiatric disorders. In: Schenck C, Hogl B, Videnovic A (eds). Rapid-eye-movement sleep behavior disorder. Cham: Springer 2019 : 123–134. doi: 10.1007/978-3-319-90152-7_10.

47. Barone DA. Secondary RBD: not just neurodegeneration. Sleep Med Rev 2024; 76 : 101938. doi: 10.1016/ j.smrv.2024.101938.

48. Lai YY, Kodama T, Siegel JM. Changes in monoamine release in the ventral horn and hypoglossal nucleus linked to pontine inhibition of muscle tone: an in vivo microdialysis study. J Neurosci 2001; 21 (18): 7384–7391. doi: 10.1523/JNEUROSCI.21-18-07384.2001.

49. Luppi PH, Clement O, Garcia SV et al. New aspects in the pathophysiology of rapid eye movement sleep behavior disorder: the potential role of glutamate, gamma-aminobutyric acid, and glycine. Sleep Med 2013; 14 (8): 714–718. doi: 10.1016/j.sleep.2013.02.004.

50. Barrow J, Vendrame M. Treatment of REM sleep behavior disorder with trazodone: report of three cases. J Clin Sleep Med 2024; 20 (5): 821–823. doi: 10.5664/ jcsm.10970.

51. Feemster J, St Louis EK, Auger RR. Differential impact on isolated REM sleep without atonia by varying antidepressant therapies. J Affect Disord Rep 2020; 1 : 100007. doi: 10.1016/j.jadr.2020.100007.

52. Boeve BF. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci 2010; 1184 : 15–54. doi: 10.1111/j.1749-6632.2009.05115.x.

53. Bonakis A, Economou NT, Papageorgiou SG et al. Agomelatine may improve REM sleep behavior disorder symptoms. J Clin Psychopharmacol 2012; 32 (5): 732–734. doi: 10.1097/JCP.0b013e31826866f8.

54. Lam SP, Fong SY, Ho CK et al. Parasomnia among psychiatric outpatients: a clinical, epidemiologic, cross-sectional study. J Clin Psychiatry 2008; 69 (9): 1374–1382. doi: 10.4088/jcp.v69n0904.

55. Postuma RB, Gagnon JF, Tuineaig M et al. Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal? Sleep 2013; 36 (11): 1579–1585. doi: 10.5665/sleep.3102.

56. Hoque R, Chesson AL. Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis. J Clin Sleep Med 2010; 6 (1): 79–83.

57. Peralta AR, Arnaldi D, Neutel D. Miscellaneous topics. In: Bassetti C, McNicholas W, Paunio T et al. (eds). Sleep medicine textbook. Regensburg: European Sleep Research Society 2021 : 565–576.

58. Dostálová S. Syndrom neklidných nohou: terapeutický problém. In: Příhodová I, Dostálová S (eds). Spánková medicína v kazuistikách. Praha: EEZY Publishing 2023 : 289–296.

59. Garcia-Malo C, Novo Ponte S, Garcia-Borreguero D. Sleep related movement disorders –⁠ pathophysiology. In: Bassetti CL, McNicholas W, Paunio T et al. (eds). ESRS sleep medicine textbook. Regensburg: European Sleep Research Society 2021 : 587–597.

60. Khachatryan SG, Ferri R, Fulda S et al. Restless legs syndrome: over 50 years of European contribution. J Sleep Res 2022; 31 (4): e13632. doi: 10.1111/jsr.13632.

61. Kolla BP, Mansukhani MP, Bostwick JM. The influence of antidepressants on restless legs syndrome and periodic limb movements: a systematic review. Sleep Med Rev 2018; 38 : 131–140. doi: 10.1016/j.smrv.2017.06.002.

62. Hoxha O, Jairam T, Kendzerska T et al. Association of periodic limb movements with medication classes: a retrospective cohort study. Neurology 2022; 98 (15): e1585–e1595. doi: 10.1212/WNL.0000000000200012.

63. Fulda S, Kloiber S, Dose T et al. Mirtazapine provokes periodic leg movements during sleep in young healthy men. Sleep 2013; 36 (5): 661–669. doi: 10.5665/sleep.2622.

64. Buskova J, Vorlova T, Pisko J et al. Severe sleep-related movement disorder induced by sertraline. Sleep Med 2012; 13 (6): 769–770. doi: 10.1016/j.sleep.2012.01.006.

65. Saber WK, Almuallim AR, Algahtani R. Restless legs syndrome and the use of antipsychotic medication: an updated literature review. Cureus 2022; 14 (8): e27821. doi: 10.7759/cureus.27821.

66. Grote L, Puertas F. Assesment of sleep disorders and diagnostic procedures –⁠ the clinical interview and clinical examination. In: Bassetti CL, McNicholas W, Paunio T et al. (eds). ESRS sleep medicine textbook. Regensburg: European Sleep Research Society 2021 : 167–180.

67. Silber MH, Buchfuhrer MJ, Earley CJ et al. The management of restless legs syndrome: an updated algorithm. Mayo Clin Proc 2021; 96 (7): 1921–1937. doi: 10.1016/j.mayocp.2020.12.026.

68. Garcia-Borreguero D, Allen RP, Kohnen R et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007; 8 (5): 520–530. doi: 10.1016/j.sleep.2007.03.022.

69. de Baat C, Verhoeff MC, Ahlberg J et al. Medications and addictive substances potentially inducing or attenuating sleep bruxism and/or awake bruxism. J Oral Rehabil 2021; 48 (3): 343–354. doi: 10.1111/joor.13061.

70. Garrison SR, Dormuth CR, Morrow RL et al. Nocturnal leg cramps and prescription use that precedes them: a sequence symmetry analysis. Arch Intern Med 2012; 172 (2): 120–126. doi: 10.1001/archinternmed.2011.1029.

71. Winkelmann J. Nocturnal leg cramps. [online]. Dostupné z: chrome-extension: //efaidnbmnnnibpcajpcglclefindmkaj/https: //www.goldcoastvascular.com.au/files/Nocturnallegcramps_UTD.pdf.